DJIA 16,268.74 210.39 1.31%
NASDAQ 4,711.32 75.22 1.62%
S&P 500 1,934.34 20.49 1.07%
market minute promo

Acorda Therapeutics, Inc. (NASDAQ: ACOR)

32.09 0.32 (1.01%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

ACOR $32.09 1.01%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $32.09
Previous Close $31.77
Daily Range $31.40 - $32.56
52-Week Range $27.92 - $45.45
Market Cap $1.4B
P/E Ratio 132.38
Dividend (Yield) $0.00 (0.0%)
Volume 635,534
Average Daily Volume 712,094
Current FY EPS -$0.01




Drug Makers

Acorda Therapeutics, Inc. (ACOR) Description

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS. Website:

News & Commentary

3 Biotech Stocks Bucking the Stock Market Crash

The stock market may be crashing, but these three biotech stocks couldn't care less.

Approval Of Repatha May Give Amgen A $5B Boost.

The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure

Kyle Bass's Latest IPR Missile Ventures Into Biologics And Threatens Amgen's $5B Enbrel Drug

Acorda Therapeutics (ACOR) Jumps: Stock Moves 8.3% Higher

Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data

Benzinga's Top #PreMarket Gainers

Acorda (ACOR) Gets Favorable Outcome in Ampyra IPR Issue

Acorda Therapeutics (ACOR) Stock Climbs After Panel Dismisses Patent Challenge

Why Acorda Therapeutics, Inc. Stock Surged Higher Today

Acorda Therapeutics' stock soared today after the USPTO declined to review two key patents for the company's multiple sclerosis drug Ampyra.

See More ACOR News...

ACOR's Top Competitors

ACOR $32.09 (1.01%)
Current stock: ACOR
AMGN $149.70 (1.52%)
Current stock: AMGN
CELG $117.85 (2.07%)
Current stock: CELG
GILD $102.94 (1.43%)
Current stock: GILD